Cohance Lifesciences Falls 3.80% Amid Downgrade and 52-Week Low: Key Weekly Developments

29 December 2025: Downgrade to Sell Amid Mixed Signals

Cohance Lifesciences opened the week at Rs.532.25, closing down 1.00% on the day as MarketsMOJO downgraded the stock from Strong Sell to Sell on 26 December 2025. This rating revision reflected a nuanced shift in technical outlook despite ongoing financial challenges. The company’s return on equity stood at a modest 9.1%, while management efficiency was higher at 21.07%. However, the stock traded at a premium price-to-book ratio of 5.4 despite a 53.08% decline over the past year. The downgrade was driven by weak profitability trends, including a 42.4% drop in profit before tax excluding other income and a 39.7% contraction in net profit after tax over six months. Technical indicators showed a mildly bearish stance, with mixed signals from MACD, RSI, and Bollinger Bands. The stock closed near its 52-week low, signalling persistent pressure.

30 December 2025: Technical Momentum Turns Bearish

The stock declined further to Rs.527.70, down 0.85%, as technical momentum deteriorated. The Moving Average Convergence Divergence (MACD) remained bearish on the weekly chart, while the Relative Strength Index (RSI) showed a neutral to mildly bullish monthly reading but no clear weekly signal. Daily moving averages stayed bearish, and Bollinger Bands indicated ongoing downward pressure. The Know Sure Thing (KST) oscillator and Dow Theory readings presented mixed signals, with weekly mildly bullish but monthly bearish trends. On-balance volume (OBV) showed no decisive trend, reflecting limited buying interest. The downgrade to Sell was reinforced by these technical weaknesses amid a broader market that remained resilient.

31 December 2025: Bearish Technical Downturn Continues

On the last trading day of 2025, the stock marginally recovered to Rs.528.50, up 0.15%, but technical indicators worsened. The overall technical trend shifted from mildly bearish to outright bearish, with MACD bearish weekly and mildly bearish monthly. The RSI remained neutral weekly but bullish monthly, suggesting potential oversold conditions. Daily moving averages and Bollinger Bands confirmed the bearish bias. The stock hovered near its 52-week low of Rs.518.00, far below its 52-week high of Rs.1,328.20. The MarketsMOJO Mojo Score stood at 34.0 with a Sell rating, reflecting cautious sentiment amid sustained underperformance relative to the Sensex and sector peers.

1 January 2026: Downgrade to Strong Sell Amid Weak Financials

The stock declined to Rs.523.50, down 0.95%, as MarketsMOJO downgraded Cohance Lifesciences from Sell to Strong Sell on 31 December 2025. This reflected deteriorating financial performance, including a 42.4% drop in profit before tax excluding other income and a 39.7% contraction in net profit after tax over six months. The price-to-book ratio remained elevated at 5.3 despite weak returns. Technical indicators turned more bearish, with MACD bearish weekly and mildly bearish monthly, daily moving averages bearish, and Bollinger Bands bearish on weekly and monthly charts. The stock remained near its 52-week low, underscoring persistent negative sentiment. The Mojo Score declined to 28.0, signalling heightened risk amid ongoing operational challenges and valuation concerns.

2 January 2026: Stock Hits 52-Week Low Amid Continued Downtrend

Cohance Lifesciences closed the week at Rs.517.15, down 1.21% on 2 January 2026, marking a fresh 52-week low of Rs.515.3 during the session. The stock’s decline extended a two-day losing streak, underperforming the Pharmaceuticals & Biotechnology sector by 1.87%. It traded below all key moving averages, signalling sustained bearish momentum. Despite strong management efficiency with a ROE of 21.07%, the company’s operating cash flow hit a recent low of Rs.301.03 crores, and quarterly profit before tax excluding other income fell sharply. The stock’s one-year return was -53.70%, significantly lagging the Sensex’s 7.19% gain. The full pledge of promoter shares added to downside risk, as market volatility could trigger forced selling. The downgrade to Strong Sell and the 52-week low highlight the stock’s ongoing struggles amid a broader market rally.

Key Takeaways

Negative Price Performance: Cohance Lifesciences declined 3.80% over the week, sharply underperforming the Sensex’s 1.35% gain. The stock’s persistent downtrend culminated in a 52-week low of Rs.515.3 on 2 January 2026.

Downgrades Reflect Weak Fundamentals: The company’s rating was downgraded twice, from Strong Sell to Sell on 26 December 2025 and then back to Strong Sell on 31 December 2025, driven by deteriorating profitability, weak operating cash flow, and expensive valuation metrics.

Technical Indicators Bearish: Key technical signals including MACD, moving averages, and Bollinger Bands remained bearish throughout the week, with only RSI showing occasional bullish or neutral signals. Volume indicators failed to confirm any sustained buying interest.

Valuation and Risk Factors: Despite a high price-to-book ratio above 5.3 and a modest ROE of 9.1%, the stock’s full promoter share pledge and weak earnings growth pose significant downside risks in volatile markets.

Sector and Market Context: While the Pharmaceuticals & Biotechnology sector and broader market indices showed resilience and gains, Cohance Lifesciences lagged considerably, highlighting company-specific challenges amid a generally positive environment.

Conclusion

Cohance Lifesciences Ltd’s performance over the week ending 2 January 2026 was marked by continued weakness in both price and fundamentals. The stock’s 3.80% decline and fresh 52-week low underscore ongoing challenges, including deteriorating profitability, stretched valuation, and bearish technical momentum. Multiple downgrades by MarketsMOJO to a Strong Sell rating reflect heightened caution amid these adverse trends. Despite strong management efficiency and a conservative debt profile, the company’s financial and operational headwinds have weighed heavily on investor sentiment. Until there is clear evidence of sustained earnings recovery and technical stabilisation, the outlook remains subdued relative to the broader market and sector peers.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today